ETIDRONIC ACID

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C2H8O7P2
Molecular Weight	206.0282
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=DBVJJBKOTRCVKF-UHFFFAOYSA-N

InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)

HIDE SMILES / InChI

Molecular Formula	C2H8O7P2
Molecular Weight	206.0282
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s058lbl.pdf |

Etidronate is a salt of etidronic acid (brand name Didronel, also known as EHDP) a diphosphonate, which is indicated for the treatment of symptomatic Paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis. This drugs acts primarily on bone. It can inhibit the formation, growth, and dissolution of hydroxyapatite crystals and their amorphous precursors by chemisorption to calcium phosphate surfaces. Inhibition of crystal resorption occurs at lower doses than are required to inhibit crystal growth. Both effects increase as the dose increases. Preclinical studies indicate etidronate disodium does not cross the blood-brain barrier. Didronel is not metabolized. The amount of drug absorbed after an oral dose is approximately 3 percent. Bisphosphonates, when attached to bone tissue, are absorbed by osteoclasts, the bone cells that breaks down bone tissue. Although the mechanism of action of non-nitrogenous bisphosphonates has not been fully elucidated, available data suggest that they bind strongly to hydroxyapatite crystals in the bone matrix, preferentially at the sites of increased bone turnover and inhibit the formation and dissolution of the crystals. Other actions may include direct inhibition of mature osteoclast function, promotion of osteoclast apoptosis, and interference with osteoblast-mediated osteoclast activation. Etidronic acid may promote osteoclast apoptosis by competing with adenosine triphosphate (ATP) in the cellular energy metabolism. The osteoclast initiates apoptosis and dies, leading to an overall decrease in the breakdown of bone.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hydroxyapatite 20 Target ID: CHEMBL2363055 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16046206	Antagonist 2778
ATP 10 Target ID: CHEMBL2366048 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21111853	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Paget’s disease of bone 12 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s058lbl.pdf	Primary		Approved 8429	DIDRONEL Approved Use Didronel is indicated for the treatment of symptomatic Paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis. Paget’s Disease: Didronel is indicated for the treatment of symptomatic Paget's disease of bone. Didronel therapy usually arrests or significantly impedes the disease process as evidenced by: --Symptomatic relief, including decreased pain and/or increased mobility (experienced by 3 out of 5 patients). --Reductions in serum alkaline phosphatase and urinary hydroxyproline levels (30 percent or more in 4 out of 5 patients). --Histomorphometry showing reduced numbers of osteoclasts and osteoblasts, and more lamellar bone formation. Bone scans showing reduced radionuclide uptake at pagetic lesions. In addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. In many patients, the disease process will be suppressed for a period of at least 1 year following cessation of therapy. The upper limit of this period has not been determined. The effects of the Didronel treatment in patients with asymptomatic Paget's disease have not been studied. However, Didronel treatment of such patients may be warranted if extensive involvement threatens irreversible neurologic damage, major joints, or major weight-bearing bones. Heterotopic Ossification: Didronel is indicated in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel reduces the incidence of clinically important heterotopic bone by about two-thirds. Among those patients who form heterotopic bone, Didronel retards the progression of immature lesions and reduces the severity by at least half. Follow-up data (at least 9 months posttherapy) suggest these benefits persist. In total hip replacement patients, Didronel does not promote loosening of the prosthesis or impede trochanteric reattachment. In spinal cord injury patients, Didronel does not inhibit fracture healing or stabilization of the spine. Launch Date 2.4192E11
Heterotopic ossification 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s058lbl.pdf	Preventing		Approved 8429	DIDRONEL Approved Use Didronel is indicated for the treatment of symptomatic Paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis. Paget’s Disease: Didronel is indicated for the treatment of symptomatic Paget's disease of bone. Didronel therapy usually arrests or significantly impedes the disease process as evidenced by: --Symptomatic relief, including decreased pain and/or increased mobility (experienced by 3 out of 5 patients). --Reductions in serum alkaline phosphatase and urinary hydroxyproline levels (30 percent or more in 4 out of 5 patients). --Histomorphometry showing reduced numbers of osteoclasts and osteoblasts, and more lamellar bone formation. Bone scans showing reduced radionuclide uptake at pagetic lesions. In addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. In many patients, the disease process will be suppressed for a period of at least 1 year following cessation of therapy. The upper limit of this period has not been determined. The effects of the Didronel treatment in patients with asymptomatic Paget's disease have not been studied. However, Didronel treatment of such patients may be warranted if extensive involvement threatens irreversible neurologic damage, major joints, or major weight-bearing bones. Heterotopic Ossification: Didronel is indicated in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel reduces the incidence of clinically important heterotopic bone by about two-thirds. Among those patients who form heterotopic bone, Didronel retards the progression of immature lesions and reduces the severity by at least half. Follow-up data (at least 9 months posttherapy) suggest these benefits persist. In total hip replacement patients, Didronel does not promote loosening of the prosthesis or impede trochanteric reattachment. In spinal cord injury patients, Didronel does not inhibit fracture healing or stabilization of the spine. Launch Date 2.4192E11

PubMed

Title	Date	PubMed
Possibility of "distraction arthrogenesis": first report in rabbit model.	2001	11793183
Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate.	2001	11793169
Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis.	2001	11484098
Initiation of osteoporosis treatment after bone mineral density testing.	2001	11444079
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.	2001 Dec	11728926
[Therapy of osteoporosis. Risk factors alone are not an indication].	2001 Dec 6	11813710
Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.	2001 Feb	11405286
Treatment of osteoporosis with bisphosphonates.	2001 Feb	11285996
Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.	2001 Jan	11165950
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].	2001 Jul 14	11484428
Prevention of corticosteroid induced osteoporosis in inpatients recently discharged from a tertiary teaching hospital.	2001 Mar	11296960
Evidence-based medicine: putting theory into practice.	2001 Mar	11291467
Once-a-week alendronate (Fosamax).	2001 Mar 19	11257718
Prevention and treatment of osteoporosis.	2001 Mar-Apr	11333463
Incadronate and etidronate accelerate phosphate-primed mineralization of MC4 cells via ERK1/2-Cbfa1 signaling pathway in a Ras-independent manner: further involvement of mevalonate-pathway blockade for incadronate.	2001 May	11430477
Risedronate: clinical usage.	2001 May	11406915
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.	2001 May	11344179
The role of combination treatment for osteoporosis.	2001 May	11344178
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.	2001 May	11344045
[Therapy of osteoporosis from the viewpoint of evidence-based medicine].	2001 May 15	11395991
The effect of risedronate on the risk of hip fracture in elderly women.	2001 May 31	11386283
[Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].	2001 Nov	11770280
Familial fibrodysplasia ossificans progressiva: trial with etidronate disodium.	2001 Nov	11721075
Role of alendronate and risedronate in preventing and treating osteoporosis.	2001 Nov	11718433
Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro.	2001 Nov	11697801
Conventional treatment of hypercalcemia of malignancy.	2001 Nov 15	11757206
A method to assess the proportion of treatment effect explained by a surrogate endpoint.	2001 Nov 15	11746311
Risedronate treatment and extended fracture protection in postmenopausal women.	2001 Nov-Dec	11791630
Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates.	2001 Oct	11730262
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.	2001 Oct	11730260
Alendronate for the treatment of osteoporosis in men.	2001 Oct	11730259
Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.	2001 Oct	11707007
Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.	2001 Oct	11595618
Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate ((186)Re HEDP) after failed treatment with medication--initial results of a prospective study.	2001 Oct	11568349
[Osteoporosis. Fracture as alarm signal].	2001 Oct 11	11721665
Bisphosphonates for osteoporosis.	2001 Sep	11586803
Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures.	2001 Sep	11557372
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.	2001 Sep	11535725
Pharmacologic therapy for the treatment and prevention of osteoporosis.	2001 Sep	11532658
[Risedronate now also approved for hip fractures. Study discloses significant risk reduction in proximal femoral neck fractures].	2001 Sep 6	11584532
[Optimizing treatment of osteoporosis. Rapidly effective therapy lowers fracture risk in 1 year up to 70%].	2001 Sep 6	11584531
Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats.	2002 Feb 8	11724771

Patents

Sample Use Guides

In Vivo Use Guide

should be taken as a single, oral dose. Paget’s Disease: Initial Treatment Regimens: 5 to 10 mg/kg/day, not to exceed 6 months, or 11 to 20 mg/kg/day, not to exceed 3 months. The recommended initial dose is 5 mg/kg/day for a period not to exceed 6 months. Doses above 10 mg/kg/day should be reserved for when 1) lower doses are ineffective or 2) there is an overriding need to suppress rapid bone turnover (especially when irreversible neurologic damage is possible) or reduce elevated cardiac output. Doses in excess of 20 mg/kg/day are not recommended.

Route of Administration: Oral

In Vitro Use Guide

In vitro cytotoxicity of etidronic acid to MCF-7 cells was estimated on the basis of clonogenicity assays, while cell cycle effects were determined by using flow cytometry. A 24-hour treatment with etidronic acid (10 mM) with or without strontium chloride was cytototoxic to MCF-7cells. Etidronic acid (1, 10 mM) caused a decrease in the S-phase population and an increase in the G2/M population. Treatment of MCF-7 human breast cancer cells with etidronic acid (10 mM) for six hours caused mutations in exons 6 and 8 of the p53 gene in MCF-7 cells.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:53:39 UTC 2023` Edited by `admin` on `Sat Dec 16 17:53:39 UTC 2023`
Record UNII	M2F465ROXU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ETIDRONIC ACID

Official Name

English

ETIDRONATE

Common Name

English

ETIDRONIC ACID [INCI]

Common Name

English

M05BA01

Code

English

(1-Hydroxyethylidene)diphosphonic acid

Systematic Name

English

HYDROXYETHYLIDENE-1,1-DIPHOSPHONIC ACID

Systematic Name

English

etidronic acid [INN]

Common Name

English

ETIDRONIC ACID [HSDB]

Common Name

English

(1-HYDROXY-ETHYLIDENE)DIPHOSPHONIC ACID

Systematic Name

English

NSC-227995

Code

English

PHOSPHONIC ACID, (1-HYDROXYETHYLIDENE)BIS-

Common Name

English

ETIDRONIC ACID [USAN]

Common Name

English

PHOSPHONIC ACID, P,P'-(1-HYDROXYETHYLIDENE)BIS-

Systematic Name

English

ETIDRONATE [VANDF]

Common Name

English

Etidronic acid [WHO-DD]

Common Name

English

1-HYDROXYETHANE-1,1-BISPHOSPHONIC ACID

Systematic Name

English

ETIDRONIC ACID [MART.]

Common Name

English

OEDP

Common Name

English

ETIDRONIC ACID [MI]

Common Name

English

Classification Tree Code System Code

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1096

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 699

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1144

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 691

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1247

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

WHO-ATC

M05BB01

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

WHO-VATC

QM05BA01

Created by admin on Sat Dec 16 17:53:42 UTC 2023 , Edited by admin on Sat Dec 16 17:53:42 UTC 2023

LIVERTOX

386

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

NDF-RT

N0000175579

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 561

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1081

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1082

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

NCI_THESAURUS

C443

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1094

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 625

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 951

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 724

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 670

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 908

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1089

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 641

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 993

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1236

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

WHO-ATC

M05BA01

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 921

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1035

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1132

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 801

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 323

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1093

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 728

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 447

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

WHO-VATC

QM05BB01

Created by admin on Sat Dec 16 17:53:42 UTC 2023 , Edited by admin on Sat Dec 16 17:53:42 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 880

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 887

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

NCI_THESAURUS

C67439

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 140

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

NDF-RT

N0000007707

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Food Contact Sustance Notif, (FCN No.)

FCN NO. 911

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

Code System Code Type Description

ECHA (EC/EINECS)

220-552-8

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

NSC

227995

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

PUBCHEM

3305

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

INN

2758

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

FDA UNII

M2F465ROXU

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

MERCK INDEX

m5182

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

Merck Index

DRUG BANK

DB01077

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

MESH

D012968

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

LACTMED

Etidronate

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

EPA CompTox

DTXSID6023028

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

DRUG CENTRAL

1098

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

HSDB

5898

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

DAILYMED

M2F465ROXU

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

CHEBI

4907

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

IUPHAR

7184

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

NCI_THESAURUS

C1332

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

SMS_ID

100000082093

Created by admin on Sat Dec 16 17:53:42 UTC 2023 , Edited by admin on Sat Dec 16 17:53:42 UTC 2023

PRIMARY

RXCUI

1356715

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

WIKIPEDIA

Etidronic acid

Created by admin on Sat Dec 16 17:53:42 UTC 2023 , Edited by admin on Sat Dec 16 17:53:42 UTC 2023

PRIMARY

ChEMBL

CHEMBL871

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

CAS

2809-21-4

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

RXCUI

42682

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

ALTERNATIVE

EVMPD

SUB07299MIG

Created by admin on Sat Dec 16 17:53:41 UTC 2023 , Edited by admin on Sat Dec 16 17:53:41 UTC 2023

PRIMARY

Related Record Type Details


					HWB1KVT9Z5

MONOPOTASSIUM ETIDRONATE

SALT/SOLVATE -> PARENT


					4SQ327I33M

ETIDRONIC ACID MONOHYDRATE

SOLVATE->ANHYDROUS


					FF53VF097S

ETIDRONATE PENTAPOTASSIUM MONOHYDRATE

SALT/SOLVATE -> PARENT


					DV7W6W681S

RHENIUM RE-186 ETIDRONATE

SALT/SOLVATE -> PARENT


					CVI36ET72E

TETRAPOTASSIUM ETIDRONATE

SALT/SOLVATE -> PARENT


					8SS5TWI75G

DIPOTASSIUM ETIDRONATE

SALT/SOLVATE -> PARENT


					M16PXG993G

ETIDRONATE DISODIUM

SALT/SOLVATE -> PARENT


					K49SH0Z84H

DICALCIUM ETIDRONATE

SALT/SOLVATE -> PARENT

TECHNETIUM TC-99M ETIDRONATE KIT

SALT/SOLVATE -> PARENT


					43663WR0HQ

ETIDRONATE PENTAPOTASSIUM

SALT/SOLVATE -> PARENT


					6Z2J8X3Q6U

TRISODIUM ETIDRONATE

SALT/SOLVATE -> PARENT


					2R11JA60QK

ETIDRONATE PENTASODIUM

SALT/SOLVATE -> PARENT


					CZZ9T1T1X4

ETIDRONATE TETRASODIUM

SALT/SOLVATE -> PARENT


					BCZ8ETH6PD

MONOSODIUM ETIDRONATE

SALT/SOLVATE -> PARENT


					13W7DMI45X

TECHNETIUM TC-99M ETIDRONATE

SALT/SOLVATE -> PARENT


					XWW2JNQ850

RHENIUM RE-188 ETIDRONATE

SALT/SOLVATE -> PARENT


					RB325UD2VG

TRIPOTASSIUM ETIDRONATE

SALT/SOLVATE -> PARENT

Related Record Type Details


					M2F465ROXU

ETIDRONIC ACID

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s058lbl.pdf |

CNS Activity

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s058lbl.pdf |